Header
Header
Article

ImmunoGen shares tank on ovarian cancer trial failure


Although an improvement in progression-free survival was shown in patients with high expression of the drug’s target, it did not reach statistical significance. The company’s shares lost half their value Friday.

Source link

Back to top button